Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science – PR Newswire (press release)

Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in SciencePR Newswire (press release)CARLSBAD, Calif., Oct. 23, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc (NASDAQ: IONS), the leader in antisense therapeutics, today announced that C. Frank Bennett, Ph.D., senior vice president of research and franchise leader for neurological …and more »

Read More

Antisense Therapeutics (ATHJF) Churns Higher 111.54% For the Week – Northfield Review (press release)

Antisense Therapeutics (ATHJF) Churns Higher 111.54% For the WeekNorthfield Review (press release)Antisense Therapeutics (ATHJF) shares are showing positive signals short-term as the stock has finished higher by 111.54% for the week. In taking a look at recent performance, we can see that shares have moved 10.00% over the past 4-weeks, 89.66% over …Trading Check: PPO Reading Above the Signal Line on Shares of Antisense Therapeutics (ATHJF)LNRall 3 news articles »

Read More

AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells – FierceBiotech

FierceBiotechAstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cellsFierceBiotechNow AstraZeneca and Ionis are working together to investigate a new way to target beta cells with antisense oligonucleotides (ASOs)—and they have early evidence the approach may help restore the functioning of those vital cells. ASOs are synthetic …Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical OncologyPR Newswire (press release)Ionis Pharma’s danvatirsen shows positive effect in mid-stage head and neck cancer study; shares up 4%Seeking Alphaall 5 news articles »

Read More

Ionis Pharmaceuticals (IONS) Reports New Phase 1b/2 Trial Data on Danvatirsen (formerly IONIS-STAT3-2.5Rx, aka … – StreetInsider.com

Ionis Pharmaceuticals (IONS) Reports New Phase 1b/2 Trial Data on Danvatirsen (formerly IONIS-STAT3-2.5Rx, aka …StreetInsider.comThe study showed clinical and safety results from a phase 1b/2 trial evaluating danvatirsen, a Generation 2.5 antisense therapy targeting signal transducer and activator of transcription 3 (STAT3), in combination with durvalumab, AstraZeneca’s anti-PD …

Read More

Antisense and RNAi Therapeutics Market: In-Depth Analysis & Marginal Revenue Growth 2016 – 2024 – ZMR News Journal (press release) (blog)

ZMR News Journal (press release) (blog)Antisense and RNAi Therapeutics Market: In-Depth Analysis & Marginal Revenue Growth 2016 – 2024ZMR News Journal (press release) (blog)Zion Market Research has announced the addition of the “Antisense and RNAi Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024“, The report classifies the global Antisense and RNAi Therapeutics Market …and more »

Read More

Antisense Oligonucleotides Market by Revenue, Present Scenario and Growth Prospects To 2026 – The Industry Chronicle (press release) (blog)

The Industry Chronicle (press release) (blog)Antisense Oligonucleotides Market by Revenue, Present Scenario and Growth Prospects To 2026The Industry Chronicle (press release) (blog)The Antisense Oligonucleotides Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Antisense Oligonucleotides Market research report. The report has been added in his large database by …and more »

Read More

Antisense Oligonucleotides Market Global Industry Size, Growth, Trends and Forecast 2017–2027 – Digital Journal

Antisense Oligonucleotides Market Global Industry Size, Growth, Trends and Forecast 2017–2027Digital JournalValley Cottage, NY — (SBWIRE) — 10/19/2018 — Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by …

Read More

Global Antisense & RNAi Therapeutics Market 2018 Perspective – Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis … – Market Biz Tribune (blog)

Global Antisense & RNAi Therapeutics Market 2018 Perspective – Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis …Market Biz Tribune (blog)Global Antisense & RNAi Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023 details the summary and describes the Product/Industry scope within the market. The report also discusses the market review and …

Read More

Global Antisense & RNAi Therapeutics Market 2018 – Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis … – CoinIndeed

CoinIndeedGlobal Antisense & RNAi Therapeutics Market 2018 – Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis …CoinIndeedMarketresearchpro recently published Global Antisense & RNAi Therapeutics Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key …

Read More

Global Integrin Alpha 4 Market Outlook 2018-2025: Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, BioMAS Ltd – The Market Insights (press release) (blog)

The Market Insights (press release) (blog)Global Integrin Alpha 4 Market Outlook 2018-2025: Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, BioMAS LtdThe Market Insights (press release) (blog)The well-established players in the market are Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, BioMAS Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, …and more »

Read More

Global Antisense and RNAi Therapeutics Market 2018 – Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam … – Tokeniest

Chronicle IndiaGlobal Antisense and RNAi Therapeutics Market 2018 – Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam …TokeniestMarketresearchpro recently published Global Antisense and RNAi Therapeutics Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key …Antisense and RNAi Therapeutics Market by 2023 Analysis, Growth, Drivers, Challenges, Opportunities, Manufacturers …Chronicle Indiaall 2 news articles »

Read More

Delving into These Stocks PSM Holdings, Inc. (OTCPK:PSMH), Antisense Therapeutics Limited (ASX:ANP): A Look at … – Zeeland Press

Delving into These Stocks PSM Holdings, Inc. (OTCPK:PSMH), Antisense Therapeutics Limited (ASX:ANP): A Look at …Zeeland PressThe Piotroski F-Score of PSM Holdings, Inc. (OTCPK:PSMH) is 4. The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. A score of nine …and more »

Read More

Researchers Behind Spinraza Win Breakthrough Prize – Forbes

ForbesResearchers Behind Spinraza Win Breakthrough PrizeForbesBennett joined Ionis, originally called Isis Pharmaceuticals, three decades ago, when Isis’ founder, Stan Crooke, was leaving big pharma to start a smaller biotechnology firm to focus on a technology called antisense. Antisense works by using a strand …Breakthrough Prize to CSHL professor for SMA researchPR Newswire (press release)For making untreatable disease treatable, Frank Bennett of Ionis shares $3 million Breakthrough PrizeThe San Diego Union-TribuneWinners of the 2019 Breakthrough Prize in Life Sciences, Fundamental Physics and Mathematics AnnouncedPR Newswire UK (press release)Newsdayall 15 news articles »

Read More

It Seems ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) Will Go Down. Just Reported More … – The Cardinal Weekly (press release)

It Seems ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) Will Go Down. Just Reported More …The Cardinal Weekly (press release)The stock of ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) registered an increase of 1500% in short interest. ATHJF’s total short interest was 1,600 shares in October as published by FINRA. Its up 1500% from 100 shares, reported …and more »

Read More

What’s ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) Upside After This Short Interest … – Thorold News

What’s ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) Upside After This Short Interest …Thorold NewsThe stock of ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) registered an increase of 1500% in short interest. ATHJF’s total short interest was 1,600 shares in October as published by FINRA. Its up 1500% from 100 shares, reported …and more »

Read More

Antisense and RNAi Therapeutics Market With Top 20 Countries Data: Trends, Application, Product Types, Forecast … – The Future Gadgets

The Future GadgetsAntisense and RNAi Therapeutics Market With Top 20 Countries Data: Trends, Application, Product Types, Forecast …The Future GadgetsGlobal Market Study Antisense and RNAi Therapeutics Market Provide Forecast Report 2018 – 2025 presents an detailed analysis of the Antisense and RNAi Therapeutics which researched industry situations, market Size, growth and demands, Antisense …

Read More

Antisense Oligonucleotides Market Granular View Of Industry From Various End-Use Segments – Morgan Newspaper USA (press release) (blog)

Morgan Newspaper USA (press release) (blog)Antisense Oligonucleotides Market Granular View Of Industry From Various End-Use SegmentsMorgan Newspaper USA (press release) (blog)The extensive enlightenments regarding Global Antisense Oligonucleotides Market 2018 along with analytical data of driving factors of industry, contemporary market trends, segments, applications, and types, as well as region-wise analysis is instilled …

Read More

Global Antisense & RNAi Therapeutics Market Share 2018 and Pipeline Review 2023: Isis Pharmaceuticals/ Ionis … – Construction News

Global Antisense & RNAi Therapeutics Market Share 2018 and Pipeline Review 2023: Isis Pharmaceuticals/ Ionis …Construction NewsThe report “International Antisense & RNAi Therapeutics Market Evaluation 2018” has an estimation of the general market size in 2013 to 2023 concerning significance (US$). The Antisense & RNAi Therapeutics report introduces an exhaustive assessment of …

Read More

Global Antisense & RNAi Therapeutics Market | Share by 2018-2023: Isis Pharmaceuticals/ Ionis Pharmaceuticals … – Industry News Updates (press release) (blog)

Global Antisense & RNAi Therapeutics Market | Share by 2018-2023: Isis Pharmaceuticals/ Ionis Pharmaceuticals …Industry News Updates (press release) (blog)“The Global Antisense & RNAi Therapeutics Market report is made up of the best advice concerning the market.” The comprehensive report can aid end customers to comprehend current industry trends, Antisense & RNAi Therapeutics industry development …

Read More

Global Duchenne Muscular Dystrophy Drugs Market 2018 Perspective – Akashi Therapeutics Inc, Antisense … – Market Biz Tribune (blog)

Market Biz Tribune (blog)Global Duchenne Muscular Dystrophy Drugs Market 2018 Perspective – Akashi Therapeutics Inc, Antisense …Market Biz Tribune (blog)Actionable, reliable and all-inclusive report on Global Duchenne Muscular Dystrophy Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023 published by Fior Markets provides exhaustive research capabilities, strong …and more »

Read More